Logo image
Screening for new macrophage therapeutics
Journal article   Open access   Peer reviewed

Screening for new macrophage therapeutics

Christopher B. Rodell, Peter D. Koch and Ralph Weissleder
Theranostics, v 9(25), pp 7714-7729
01 Jan 2019
PMID: 31695796
url
https://doi.org/10.7150/thno.34421View
Published, Version of Record (VoR)CC BY-NC V4.0 Open

Abstract

Life Sciences & Biomedicine Medicine, Research & Experimental Research & Experimental Medicine Science & Technology
Myeloid derived macrophages play a key role in many human diseases, and their therapeutic modulation via pharmacological means is receiving considerable attention. Of particular interest is the fact that these cells are i) dynamic phenotypes well suited to therapeutic manipulation and ii) phagocytic, allowing them to be efficiently targeted with nanoformulations. However, it is important to consider that macrophages represent heterogeneous populations of subtypes with often competing biological behaviors and functions. In order to develop next generation therapeutics, it is therefore essential to screen for biological effects through a combination of in vitro and in vivo assays. Here, we review the state-of-the-art techniques, including both cell based screens and in vivo imaging tools that have been developed for assessment of macrophage phenotype. We conclude with a forward-looking perspective on the growing need for noninvasive macrophage assessment and laboratory assays to be put into clinical practice and the potential broader impact of myeloid-targeted therapeutics.

Metrics

10 Record Views
31 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Medicine, Research & Experimental
Logo image